Benchmark initiated coverage of Scopus BioPharma with a rating of Buy and set a new price target of $20.00

The Benchmark Company initiated coverage of Scopus BioPharma with a rating of Speculative Buy and set a new price target of $20.00

Benchmark initiated coverage of Scopus BioPharma with a rating of Buy

Benchmark initiated coverage of Scopus BioPharma with a rating of Speculative Buy and set a new price target of $20.00

Transaction Creates Global Leader in Oligonucleotide Cancer Therapeutics Combined Assets Target Broad Range of Hematological Malignancies and Solid Tumors NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics, today announced the acquisition of Los Angeles-based Olimmune Inc. Olimmune is a developer of groundbreaking oligonucleotide immunotherapies for treatment-resistant and metastatic cancers. Olimmune's lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. It is anticipated that INDs for these indications will be submitt

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael ("Rafi") Hofstein, Ph.D. to its Board of Directors ("Board"). Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders." Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been in

Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company") today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders (the "Annual Meeting"). In addition, Scop

NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). First Coast Results, Inc., the independent inspector of elections appointed by the Company for the Annual Meeting, today certified the final results of the election reporting t

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote "FOR ALL" of the Company's Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today issued a second letter to its stockholders in connection with the Company's Annual Meeting of Stockholders (the "Annual Meeting") that will be reconvened on Monday, December 20, 2021 at 11:30 a.m., Eastern time. The record date for the Annual Meeting remains August 16, 2021. If stockholders have not already voted their shares, please vote "FOR ALL" of Scopus' director nominees today by telephone, by Internet or by signin

Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recently Raised $9.75 Million in Non-Dilutive Financing; Dilution was Fully Absorbed Through the Executive Committee's Contribution Back to the Company of Warrants to Purchase Six Million Shares Financing Provides the Cash Runway to Reach Value Creation Milestones Expected Between Now and Fourth Quarter of 2022 and First Quarter of 2023 NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today mailed a letter to its stockholde

Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope National Medical Center  Dr. Kortylewski to Chair and Present at the 14th Annual RNA Consortium Meeting NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor of Duet Therapeutics. Duet Therapeutics is a wholly-owned subsidiary of Sc

DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS") and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma. The new data was presented on November 4, 2023 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC") by Marcin Kortylewski, Ph.D. Dr. Kortylewski,

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is developing novel immunotherapies to overcome treatment-resistant cancers, today announced that Marcin Kortylewski, Ph.D., Co-Founder and Senior Scientific Advisor of Duet and Professor of Immuno-Oncology at City of Hope, will be presenting at the 38th Annual Meeting of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 3-5, 2023, in San Diego, California. Details of the presentation are as follows:

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, and its pure-play immuno-oncology subsidiary, Duet BioTherapeutics, today announced that key scientific data will be will be presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer ("SITC"). SITC is being held from November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts. About Scopus BioPharma Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma's Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately 90% Ownership Stake in Duet Duet Being Positioned to Go Public in 2023 NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, announced today the completion of a series of related recapitalization transactions designed to enhance shareholder value. These transactions include the elimination of warrants to purchase appr

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced the appointment of Raphael ("Rafi") Hofstein, Ph.D. to its Board of Directors ("Board"). Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, "We are thrilled Dr. Hofstein is rejoining our Board. Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders." Dr. Hofstein is a global leader in the biopharmaceutical and biotechnology industries. Over his career, Dr. Hofstein has been in

Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present onTLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology NEW YORK, March 22, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, today announced that Alan Horsager, Ph.D., President and Chief Executive Officer of Duet BioTherapeutics, will present at the 3rd Annual STING & TLR-Targeting Therapies Summit, to be held virtually from March 22-24, 2022. Duet BioTherapeutics is a wholly-owned subsidiary of Scopus. Dr. Horsager is also Pr

Overwhelming Majority of Shares Voted by Unaffiliated Stockholderswere in Favor of Scopus' Director Nominees Lasters' Ownership Position and Annual Meeting Results are being Challenged in Court Company Believes Ultimate Outcome of Annual Meeting Will Depend on Results of Pending Cases NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company") today announced that it has filed an amendment to the Current Report on Form 8-K that was filed by the Company on December 27, 2021 with the U.S. Securities and Exchange Commission disclosing the certified voting results of the Annual Meeting of Stockholders (the "Annual Meeting"). In addition, Scop

NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0.001, of Scopus BioPharma Inc. (NASDAQ:SCPS) ("Scopus" or the "Company"), announced today that stockholders of the Company have elected Dr. Laster's two director nominees, Mordechai Saar Hacham and Joshua Levine to the Company's Board of Directors at the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"). First Coast Results, Inc., the independent inspector of elections appointed by the Company for the Annual Meeting, today certified the final results of the election reporting t

Latest Legal Claims by Laster Actually Call into Question his Stock Ownership Company Urges Stockholders to Vote "FOR ALL" of the Company's Director Nominees on the WHITE Proxy Card NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today issued a second letter to its stockholders in connection with the Company's Annual Meeting of Stockholders (the "Annual Meeting") that will be reconvened on Monday, December 20, 2021 at 11:30 a.m., Eastern time. The record date for the Annual Meeting remains August 16, 2021. If stockholders have not already voted their shares, please vote "FOR ALL" of Scopus' director nominees today by telephone, by Internet or by signin

Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies Executing Strategy to Create an Industry-Leading Portfolio of Bi-Functional Cancer Targeting Molecules Recently Raised $9.75 Million in Non-Dilutive Financing; Dilution was Fully Absorbed Through the Executive Committee's Contribution Back to the Company of Warrants to Purchase Six Million Shares Financing Provides the Cash Runway to Reach Value Creation Milestones Expected Between Now and Fourth Quarter of 2022 and First Quarter of 2023 NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: "SCPS") today mailed a letter to its stockholde

SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13D/A - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13D - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13G - Scopus BioPharma Inc. (0001772028) (Subject)

SC 13G - Scopus BioPharma Inc. (0001772028) (Subject)

1-Z - Scopus BioPharma Inc. (0001772028) (Filer)

15-12G - Scopus BioPharma Inc. (0001772028) (Filer)

8-K - Scopus BioPharma Inc. (0001772028) (Filer)

8-K - Scopus BioPharma Inc. (0001772028) (Filer)

10-Q - Scopus BioPharma Inc. (0001772028) (Filer)

DEF 14A - Scopus BioPharma Inc. (0001772028) (Filer)

PRER14A - Scopus BioPharma Inc. (0001772028) (Filer)

10-Q - Scopus BioPharma Inc. (0001772028) (Filer)

10-K/A - Scopus BioPharma Inc. (0001772028) (Filer)

10-K - Scopus BioPharma Inc. (0001772028) (Filer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

3 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

4 - Scopus BioPharma Inc. (0001772028) (Issuer)

Gainers Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 576.1% to $3.27 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 39.7 million shares, making up 55465.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $121.0 million. Lucira Health (NASDAQ:LHDX) stock increased by 512.33% to $0.68. Trading volume for Lucira Health's stock is 119.7 million as of 12:30 EST. This is 35583.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.6 million. Reshape Lifesciences (NASDAQ:RSLS) shares moved upwards by 96.73% to $13.26. The cur

Gainers Dermata Therapeutics (NASDAQ:DRMA) shares increased by 101.8% to $0.4 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 44.7 million shares, making up 5373.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.8 million. 180 Life Sciences (NASDAQ:ATNF) shares rose 79.36% to $3.39. Trading volume for this security as of 12:30 EST is 39.5 million, which is 2695.3% of its average full-day volume over the last 100 days. The company's market cap stands at $12.6 million. Palisade Bio (NASDAQ:PALI) stock increased by 61.46% to $5.2. Trading volume for this security as of 12:30 EST is 89.4 million, which is

Gainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 143.4% to $10.71 during Thursday's regular session. As of 12:30 EST, this security is trading at a volume of 20.7 million shares, making up 17470.8% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million. Quotient (NASDAQ:QTNT) shares increased by 93.95% to $0.45. Trading volume for Quotient's stock is 38.6 million as of 12:30 EST. This is 4861.7% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 million. Palisade Bio (NASDAQ:PALI) shares moved upwards by 53.59% to $2.78. The current volume of 6.2 million shares is 466.2% of Palisade

Gainers Quotient (NASDAQ:QTNT) shares increased by 129.0% to $0.44 during Tuesday's regular session. As of 12:30 EST, Quotient's stock is trading at a volume of 20.9 million, which is 8106.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.5 million. 180 Life Sciences (NASDAQ:ATNF) stock rose 67.58% to $2.08. Trading volume for this security as of 12:30 EST is 43.9 million, which is 7441.9% of its average full-day volume over the last 100 days. The company's market cap stands at $4.2 million. HTG Molecular Diagnostics (NASDAQ:HTGM) shares moved upwards by 50.81% to $4.68. As of 12:30 EST, this security is trading at a volume of

Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 50.0% to $0.12 during Monday's regular session. The current volume of 120.0K shares is 12.4% of Scopus BioPharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $2.5 million. NantHealth (NASDAQ:NH) shares increased by 28.55% to $3.6. The current volume of 183.6K shares is 205.1% of NantHealth's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $27.7 million. OncoCyte (NASDAQ:OCX) shares moved upwards by 27.29% to $0.38. The current volume of 1.0 million shares is 282.2% of OncoCyte's

Gainers Immuron (NASDAQ:IMRN) shares increased by 37.9% to $2.22 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 17.1 million shares, making up 288523.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million. Scopus BioPharma (NASDAQ:SCPS) shares increased by 25.0% to $0.1. As of 12:30 EST, this security is trading at a volume of 85.9K shares, making up 8.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million. DBV Technologies (NASDAQ:DBVT) shares moved upwards by 21.18% to $1.43. As of 12:30 EST, DBV Technologies's stock is trading

Gainers Core Scientific, Inc. (NASDAQ:CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. IsoPlexis Corporation (NASDAQ:ISO) rose 82.4% to $1.2598. Berkeley Lights announced plans to acquire IsoPlexis in all-stock transaction at $57.8 million. AMC Entertainment Holdings, Inc. (NYSE:APE) gained 77% to $1.21. AMC Entertainment Holdings Inc (NYSE:AMC) announced an equity capital raise and a debt for equity exchange. The company also proposed a vote to convert AMC Preferred Equity Units into common shares and enact a reverse stock split. ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) climbed 69% to $5.05 after the

Gainers IsoPlexis (NASDAQ:ISO) stock moved upwards by 131.1% to $1.59 during Thursday's regular session. Trading volume for IsoPlexis's stock is 33.5 million as of 12:30 EST. This is 80056.9% of its average full-day volume over the last 100 days. The company's market cap stands at $63.1 million. Scopus BioPharma (NASDAQ:SCPS) shares moved upwards by 76.61% to $0.11. As of 12:30 EST, this security is trading at a volume of 293.1K shares, making up 30.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million. ORIC Pharmaceuticals (NASDAQ:ORIC) stock moved upwards by 55.56% to $4.67. The current volume of 25.5 million shares is

Gainers Athenex (NASDAQ:ATNX) stock moved upwards by 41.4% to $0.19 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 112.5 million, which is 9232.0% of its average full-day volume over the last 100 days. The company's market cap stands at $30.0 million. Verona Pharma (NASDAQ:VRNA) stock rose 33.39% to $18.0. Trading volume for this security as of 12:30 EST is 12.3 million, which is 4920.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.3 billion. Surrozen (NASDAQ:SRZN) shares rose 18.72% to $0.57. As of 12:30 EST, this security is trading at a volume of 2.9 million shares, making up 916.4% o

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. Axcella Health Inc. (NASDAQ:AXLA) shares rose 153% to $0.4105. Axcella Health shares dipped 63% on Friday after SVB Leerink downgraded the stock from Outperform to Market Perform and lowered its price target from $6 to $2. Camber Energy, Inc. (NYSE:CEI) shares climbed 103% to $0.1257 after the company announced an anticipated effective date of December 21, 2022 for its previously-announced 1-for-50 reverse stock split. Qumu Corporation (NASDAQ:QUMU) gained 98.2% to $0.8722 after Enghouse Systems anno